Discovery of 2-Methyl-5-(1H-pyrazol-4-yl)pyridines and Related Heterocycles as Promising M4 mAChR Positive Allosteric Modulators for the Treatment of Neurocognitive Disorders.
Boqun Liu, Geoff Thompson, Manuela Jörg, Nicholas Barnes, David M Thal, Arthur Christopoulos, Ben Capuano, Celine Valant, Peter J Scammells
{"title":"Discovery of 2-Methyl-5-(1<i>H</i>-pyrazol-4-yl)pyridines and Related Heterocycles as Promising M<sub>4</sub> mAChR Positive Allosteric Modulators for the Treatment of Neurocognitive Disorders.","authors":"Boqun Liu, Geoff Thompson, Manuela Jörg, Nicholas Barnes, David M Thal, Arthur Christopoulos, Ben Capuano, Celine Valant, Peter J Scammells","doi":"10.1021/acs.jmedchem.4c01207","DOIUrl":null,"url":null,"abstract":"<p><p>The M<sub>4</sub> muscarinic acetylcholine receptor (mAChR) is a biological target for neurocognitive disorders. Compound <b>1</b> is an <i>ago</i>-PAM for the M<sub>4</sub> mAChR. Herein, we report the design, synthesis, and evaluation of novel putative M<sub>4</sub> mAChR PAMs based on <b>1</b>. These analogs were screened and then fully characterized in two functional assays (G<sub>oB</sub> protein activation and CAMYEL activation) to quantify their allosteric and <i>ago</i>-PAM properties against ACh. A selection of 7 M<sub>4</sub> PAMs were assessed for their ability to modulate ACh-mediated β-arrestin recruitment and revealed 4 distinct clusters of M<sub>4</sub> PAM activity: (1) analogs similar to <b>1</b> (<b>24d</b>), (2) analogs demonstrating only allosteric agonism (<b>23d</b>), (3) analogs with increased allosteric properties in CAMYEL activation (<b>23b</b>/<b>23f</b> and <b>24a</b>/<b>24b</b>), and (4) analogs with a biased modulatory effect toward β-arrestin recruitment (<b>23i</b>). These novel M<sub>4</sub> chemical tools disclose discrete molecular determinants, allowing further interrogation of the therapeutic roles of cAMP and β-arrestin pathways in neurocognitive disorders.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":" ","pages":"13286-13304"},"PeriodicalIF":6.8000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c01207","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The M4 muscarinic acetylcholine receptor (mAChR) is a biological target for neurocognitive disorders. Compound 1 is an ago-PAM for the M4 mAChR. Herein, we report the design, synthesis, and evaluation of novel putative M4 mAChR PAMs based on 1. These analogs were screened and then fully characterized in two functional assays (GoB protein activation and CAMYEL activation) to quantify their allosteric and ago-PAM properties against ACh. A selection of 7 M4 PAMs were assessed for their ability to modulate ACh-mediated β-arrestin recruitment and revealed 4 distinct clusters of M4 PAM activity: (1) analogs similar to 1 (24d), (2) analogs demonstrating only allosteric agonism (23d), (3) analogs with increased allosteric properties in CAMYEL activation (23b/23f and 24a/24b), and (4) analogs with a biased modulatory effect toward β-arrestin recruitment (23i). These novel M4 chemical tools disclose discrete molecular determinants, allowing further interrogation of the therapeutic roles of cAMP and β-arrestin pathways in neurocognitive disorders.
期刊介绍：
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
